New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 17, 2013
15:32 EDTRHHBY, ABBVAbbVie suspends Leukemia therapy trials. Bloomberg reports
AbbVie (ABBV) and its partner in the trials, Roche (RHHBY), have cancelled five studies on an experimental leukemia and lymphoma medicine after two patient deaths said an AbbVie spokesperson, adding that AbbVie and its partner, Roche Holding, suspended the dose-escalation portion of the studies to determine the amount of drug that is safest and most effective, reported Bloomberg Friday afternoon. Reference Link
News For ABBV;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2015
16:45 EDTRHHBYRoche to hold an investor update conference call
Subscribe for More Information
October 9, 2015
08:21 EDTRHHBYRoche to acquire Adheron Therapeutics
Subscribe for More Information
October 8, 2015
11:57 EDTRHHBYRoche says ocrelizumab cuts disability progression in studies of two forms of MS
Subscribe for More Information
06:24 EDTABBVBiogen and AbbVie's Zinbryta for MS improved cognitive results in Phase 3 study
Subscribe for More Information
October 7, 2015
07:36 EDTABBVInfectious Diseases Society of America to hold a conference
Subscribe for More Information
07:23 EDTABBVEuropean Committee Treatment & Research in Multiple Sclerosis holds meeting
Subscribe for More Information
October 6, 2015
13:32 EDTRHHBYBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
05:22 EDTRHHBYExelixis reports phase 3 pivotal trial of cobimetinib met secondary endpoint
Subscribe for More Information
October 4, 2015
14:39 EDTRHHBYPTC presents Phase 2 data on RG7800 for spinal muscular atrophy
Subscribe for More Information
October 1, 2015
13:14 EDTABBVEnanta says 34 abstracts from AbbVie chronic hep C program to be presented
Subscribe for More Information
13:04 EDTABBVAbbVie to present 34 abstracts from hep C program at The Liver Meeting 2015
Subscribe for More Information
September 30, 2015
17:48 EDTRHHBYPacific Biosciences launches new sequencing platform
Subscribe for More Information
09:12 EDTABBVInfinity Pharma reaches $130M milestone payment from AbbVie for duvelisib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use